The first results of the Biotech Co.s lymphoma program are impressive

The first results of the Biotech Co.s lymphoma program are impressive

These data will be presented at the European Hematology Association’s 2022 annual meeting on June 11, a report by ROTH Capital Partners noted.

New data on CAR-T CRISPR Therapeutics, Inc. (CRSP: NASDAQ), CTX130, shows efficacy at higher doses in patients with relapsed / refractory CD70-positive T-cell lymphoma, reported Tony Butler, analyst at ROTH Capital Partners May 12 research note. CRISPR develops gene-based medicines.

“We are struck by the initial data of CTX130,” wrote Butler, an anti-CD70, allogeneic, chimeric antigen receptor (CAR) T-cell therapy.

These dose escalation data are available in the abstract for an oral presentation to take place at the 2022 European Hematology Association (EHA) scheduled for 11 June. The talk is titled “The COBALTLYM Study of CTX130: A Phase 1 Dose Augmentation Study of CD70-CRISPR-Cas9-Engineered CAR-T allogeneic targeted CAR-T cells in patients with relapsed / refractory T-cell neoplasms (R / R) “.

Notably in the COBALTLYM study so far, the highest doses of CTX130, 300 million and 900 million cells, demonstrated a complete response (CR) rate of 29% and a disease control rate of 100% The lowest doses were 30 million and 100 million cells. The overall response rate (ORR) was found to be 71% and the disease control rate was 100%.

Jallah pointed out that these results are better than those of the drugs approved in this indication over the past 15 years: Pralatrexate, Romidepsin and Belinostat. Their associated CRs are 11%, 15%, and 11%, respectively, and their ORRs, 29%, 25%, and 26%, respectively.

CRISPR Therapeutics’ CTX130 also showed an acceptable safety profile.

“We are interested in what CRISPR Therapeutics is presenting at the EHA meeting,” wrote Butler. “If data with longer follow-up are available, possible insight into response over time and median progression-free survival will be important.”

ROTH has a Buy rating and a target price of $ 147 per share on biotech, the current share price of which is approximately $ 43.67.


You want to be the first to know of interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise ‘reports newsletter.

subscribe

Disclosures

1) Doresa Banning compiled this article for Streetwise Reports LLC and services Streetwise Reports as an independent contractor. You or your family members own securities in the following companies mentioned in the article: None. You or your family members are paid by the following companies mentioned in this article: None.

2) The following companies mentioned in this article are Streetwise Reports billboard sponsors: Nobody. Click here for important information on sponsor fees.

3) The comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officials. The information provided above is for informational purposes only and does not constitute a recommendation to buy or sell any securities.

4) The article does not constitute investment advice. Each reader is encouraged to consult their own financial professional and any action taken by a reader following the information presented here is their own responsibility. By opening this page, each reader accepts and accepts the terms of use and the complete legal disclaimer of Streetwise Reports. This article is not an investment solicitation. Streetwise Reports does not provide general or specific investment advice and information on Streetwise Reports should not be considered a recommendation to buy or sell any securities. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned in Streetwise Reports.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in the titles mentioned. Directors, officers, employees or their close relatives are prohibited from making purchases and / or sales of such securities on the open market or otherwise from the time of the decision to publish an article up to three business days after the article is published. . The above prohibition does not apply to articles which essentially reaffirm only previously published company announcements.

6) This article does not constitute medical advice. Streetwise Reports officers, employees and contractors are not licensed, medical professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosure for Roth Capital Partners, CRISPR Therapeutics PLC, May 12, 2022

A related person owns debt or stock of CRISPR Therapeutics PLC.
ROTH trades in shares of CRISPR Therapeutics PLC and, as such, buys and sells from customers primarily.
A research analyst and / or a member of the analyst’s family owns debt securities or shares of CRISPR Therapeutics PLC stock.

Not covered [NC]: ROTH does not publish research or express opinions on this security.
ROTH Capital Partners, LLC expects to receive or intend to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months. The material, information and facts discussed in this report, other than information regarding ROTH Capital Partners, LLC and its affiliates, come from sources believed to be reliable, but there is no guarantee that they are complete or accurate. This report is not to be used as a comprehensive analysis of the company, industry or security discussed in the report. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this report are subject to change without notice. An investment in the security may involve risks and uncertainties that could cause actual results to differ materially from forward-looking statements. In addition, an investment in shares can carry a high degree of risk and may not be suitable for all investors. No part of this report may be reproduced in any form without the express written consent of ROTH.

Leave a Comment

Your email address will not be published.